Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Antiviral Agents

Criteria

Inclusion Criteria:

• Documented clinical history of chronic hepatitis C and compensated liver disease

• No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Patient is pregnant or breastfeeding

• Patient is co-infected with HBV or HIV

Other protocol-defined exclusion criteria may apply.